A carregar...
A Receptor Tyrosine Kinase Inhibitor, Dovitinib (TKI-258), Enhances BMP-2-Induced Osteoblast Differentiation In Vitro
Dovitinib (TKI258) is a small molecule multi-kinase inhibitor currently in clinical phase I/II/III development for the treatment of various types of cancers. This drug has a safe and effective pharmacokinetic/pharmacodynamic profile. Although dovitinib can bind several kinases at nanomolar concentra...
Na minha lista:
| Publicado no: | Mol Cells |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Korean Society for Molecular and Cellular Biology
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4870186/ https://ncbi.nlm.nih.gov/pubmed/27025387 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.14348/molcells.2016.2300 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|